A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-16 | actual | When the study began enrolling |
| Primary completion | 2026-07-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Generalized Lipodystrophy
Intervention
- Drug: mibavademab — also filed as REGN4461
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs)
measured Up to week 68
Severity of TEAEs
measured Up to week 68
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed